This week, the FDA approved Pfizer’s Herceptin copycat, Trazimera, nearly a year after it red-lighted the drug and requested additional technical information.
Herceptin, which raked in nearly $3 billion in sales last year, is already facing biosimilar competition from Mylan, Celltrion and Samsung. Sales of Herceptin have been particularly battered by biosimilars in Europe.
Roche is now reportedly putting more focus on another breast cancer treatment, Kadcyla, to help offset lost sales from Herceptin competition.
Read the full Reuters report.